ap-5

AP5 is a potent and selective agonist for the GPR40 receptor with positive allosteric modulation of endogenous ligands (AgoPAM). AP5 demonstrates a rat hIP1 EC50 of 0.49 nM against the GPR40 receptor.

D-AP5 (D-APV) is an NMDA receptor antagonist.

DL-AP5 Sodium salt is a NMDA receptor antagonist.

DL-AP5 is the racemic form of a selective N-methyl-D-aspartate (NMDA) receptor antagonist with anticonvulsant effects.

L-AP5 is a NMDA antagonist.

AP5 sodium is a selective, potent, orally active GPR40 receptor agonist that exhibits positive allosteric modulation of endogenous ligands (AgoPAM). sodium exhibits potential for the study of type II diabetes.

AP-521, a 5-HT1A receptor antagonist, is used potentially for the treatment of anxiety.

AP-503 is a selective agonist of GPR133/ADGRD1, with an EC50 of 1.21 nM. It is utilized in research for preventing muscle-related disorders and vestibular dysfunction diseases.

CAP-53194 is a selective Plk1 inhibitor.

SNAP-5089 is a highly selective alpha1A-adrenoceptor antagonist.

TRAP-5 amide is a peptide agonist for protease-activated receptor 1 (PAR 1) [1].

AP521 is an agonist of the human 5-HT1A receptor (IC50: 94 nM).

NPEC-caged-D-AP5 is a NMDA receptor antagonist.

(S)-SNAP5114 is a selective inhibitor of GABA transport, exhibiting IC50 values of 5 μM for hGAT-3 and 21 μM for rGAT-2, and possesses anticonvulsant properties.

DL-AP5 (2-APV) lithium is a competitive antagonist of the NMDA (N-Methyl-D-aspartate) receptor. It exhibits notable analgesic activity and specifically blocks channels in the rabbit retina.

PAP508 is a PROTAC specifically targeting AR (Androgen Receptor).

Ap5A (Diadenosine pentaphosphate) is a polyphosphate diadenosine compound that functions as an adenylate kinase inhibitor, with a Ki value of 2.5 nM. This compound is applicable in cancer research.

Ap5dT is an inhibitor of cytosolic thymidine kinase and mitochondrial enzyme, with Ki values of 0.12 μM and 0.50 μM, respectively. This compound is utilized in research related to acute myeloid leukemia.

α1A-adrenoceptor antagonist

H-Ser-Phe-Leu-Leu-Arg-OH, also known as Coagulation Factor II Receptor (1-5) or Proteinase Activated Receptor 1 (1-5), is utilized in coronary heart disease (CHD) research.

AP-C5 is a compound with selective inhibition of guanosine 3',5' cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII), with a Pic50 value of 7.2 for cGMP, and can be used in the study of diarrheal diseases.

12(S)-HpETE is a monohydroperoxy polyunsaturated fatty acid (PUFA) produced by the action of platelet or leukocyte 12-lipoxygenase (12-LO) on arachidonic acid. It activates human blood leukocyte 5-LOE. 12(S)-HpETE is the mediator of many biological functions, including induction of c-fos and c-jun, activation of AP-1, and endothelium-dependent vasoconstriction. It mediates the inhibitory synaptic response to FMRF-amide in Aplysia sensory neurons and inhibits Ca2+/calmodulin-dependent protein kinase II from rat brain cortex.

1,3,5-Trihydroxy-4-prenylxanthone is a relatively potent inhibitor of phosphodiesterase type 5 (PDE5) with an IC50 of 3.0 μM; it exhibits in vitro inhibitory activity against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50 values of 56.3plusmn;0.4 and 46.0plusmn;0.3 M, respectively. It also inhibits LPS-induced NF-κB and AP-1 activations by interfering with the posttranslational modification (phosphorylation and/or ubiquitinylation) of IRAK-1, disrupting TAK1-mediated activation of IKK and MAPKs signal transduction.

T-5224 is a transcription factor c-Fos/AP-1 inhibitor that specifically inhibits the DNA-binding activity of c-Fos/c-Jun without affecting other transcription factors.